Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


